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Abstract: Breast cancer (BC) is the second leading cause of death as a result of neoplasia in 
Mexico. This study aimed to identify the direct and indirect costs of treating female outpatients 
diagnosed with BC at a Mexican public hospital. A cross-sectional, observational, analytical 
study was conducted. A total of 506 medical records were analyzed and 102 were included in 
the cost analysis. The micro-costing process was used to estimate treatment costs. A 17-item 
questionnaire was used to obtain information on direct and indirect costs. Of the 102 women 
with BC included in the study, 92.2% (94) were at Stage II, and only 7.8% at Stage I. Total 
direct costs over six months for the 82 women who had modiﬁ  ed radical mastectomy (MRM) 
surgury were US$733,821.15. Total direct costs for the 15 patients with conservative surgery 
(CS) were US$138,190.39. We found that the total economic burden in the study population 
was much higher for patients with MRM than for patients with CS.
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Introduction
Breast cancer (BC) is the most common malignancy in women and comprises 18% of 
all female cancers.1 BC remains a public-health issue on a global scale, accounting 
for one million new cases worldwide each year.1,2 The two variables most strongly 
associated with the incidence of BC are age and gender.1,3
BC poses a challenge to public health in Mexico, as the second leading cause of 
death due to cancer in women older than 25 years, second only to cervical cancer.4 
BC has the highest mortality rates in women of reproductive age; the mean age of 
death from this cause of death is 56. BC is second only to diabetes as a cause of death 
in women aged 45 to 55.5 Morbidity due to BC is increasing every year in Mexico. 
It is estimated that by 2010 the mortality rate as a result of BC in adult women will be 
13 per 100,000, and will account for 4500 deaths annually in Mexico.6
In developed countries, 50% of BCs in women are detected at stages I or II. 
In Mexico, as in other countries in a similar stage of development, detection tends to 
be delayed.7 The latest report from the Mexican Ministry of Health states that 50% of 
newly detected cases of BC are at advanced stages (III or IV).7
Long-term survival rates for many types of cancer have improved substantially 
in recent decades because of advances in early detection and treatment.8 Therapeutic 
options for a given patient depend on several different factors including age, 
menopausal status, general health, tumor location, tumor cell type, and breast size. 
The most important factor is the stage of the cancer.9 Breast-conserving surgery 
plus adjuvant chemotherapy, or radical mastectomy plus chemotherapy, are the 
options usually considered (although this choice is not without controversy).10 
A variety of treatments are available for BC, which differ in safety, efﬁ  cacy, and 
cost. Rational allocation of resources is necessary if the increasing demand for Risk Management and Healthcare Policy 2008:1 16
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health care services is to be met. This is especially true 
for public healthcare institutions.
The burden of a speciﬁ  c disease is frequently estimated 
using cost of illness (COI) and/or cost-effectiveness studies, 
especially in developed countries.11–20 Nevertheless, COI 
studies have been criticized because they do not provide 
information on the effectiveness of spending.20,21 Some 
authors support the usefulness of COI because these studies 
highlight the magnitude of the effect of an illness on society 
or a part of society.22
In Mexico (a middle-income country), these effects are 
signiﬁ  cant because BC and other chronic diseases are on the 
rise, and spending on services for their treatment competes in 
a context of scarce economic information for decision-making 
and an increasing need to prioritize resources. Knowledge 
of the cost of an illness can help policy makers to decide 
which diseases need to be addressed ﬁ  rst by health care and 
prevention policy. Furthermore, these studies can indicate 
which cures would be most valuable in reducing the burden 
of disease. For example, COI can show the federal govern-
ment what ﬁ  nancial impact a disease has on programs such 
as public health care systems and institutions, thus providing 
important information for cost-effectiveness analyses.23
COI and cost-effectiveness studies are, however, scarce 
in Mexico. To date, it is unclear how far the costs, risks, and 
efﬁ  cacy of BC interventions might outweigh those of other 
investments in health care.
The objective of the present study was to identify the costs 
(direct and indirect) involved in treating female outpatients 
diagnosed with BC at the outpatient service department 
of La Raza Hospital, a Mexican Social Security Institute 
(IMSS) hospital.
Material and methods
The study was set in the Mexican public health care system. 
It was based at the Specialized Gyno-Obstetric Medical Unit 
(UMAE) No. 3 at La Raza IMSS National Medical Center 
in Mexico City. The study period was September 1, 2007 
to November 30, 2007. The subjects were women aged 
35 to 65 diagnosed with stage I or II BC, who had a clinical 
record prior to the study and who were receiving adjuvant 
chemotherapy after conservative surgery (CS) or radical 
mastectomy (RM).
Inclusion criteria
All women 35 or older with TNM Classification of 
Malignant Tumors (TNM) stage I or II BC who had had 
conservative or radical surgery; all women with a clinical 
record prior to the study. In Mexico, very few women 
under 35 years old are diagnosed with BC.
Exclusion and elimination criteria
These criteria included women with stage I or II BC and 
another cancer, pregnant women, women with BC at higher 
stages, and women who failed to attend scheduled medical 
appointments, were hospitalized, and/or who had received 
intensive or emergency treatment during the study period.
The study was population-based, cross-sectional, obser-
vational, and analytic. All clinical records of women with 
BC (506) who attended the outpatient unit at the study site 
during the study period were analyzed and divided into two 
groups according to the inclusion criteria. Group I consisted 
of 18 women at stage I or II BC who had had conservative 
surgery (CS) and who were being treated with adjuvant che-
motherapy, radiotherapy, and/or hormone therapy. Group II 
consisted of 84 women with BC who had had radical surgery 
and who were receiving any of the same adjuvant treatments. 
The study was approved by La Raza Hospital Research Board 
and Ethics Committee. A ﬁ  xed period of 6 months was used, 
based on the length of treatment (adjuvant chemotherapy).
The micro-costing process was used.24 A 17-item ques-
tionnaire was applied to each woman in the study sample 
(102 subjects). Written consent was obtained from all par-
ticipants before administration of the questionnaire, which 
was designed to identify the resources consumed by each 
woman, and the person (usually a relative) accompanying her. 
The questionnaire included questions about patient age; type 
of work and workplace; workdays lost due to the illness and 
medical appointments; level and type of education; marital 
status; distance from hospital and travel time to hospital; 
waiting time at the hospital for the appointment and during 
the drug treatment; whether the patient was accompanied and 
relationship to the accompanying person if present; and the 
cost of meals purchased outside the home while attending 
medical appointments or treatment. The cost of waiting time 
in the hospital was calculated from the number of days the 
patient and accompanying person were absent from work.
Direct medical costs were measured, that is, laboratory 
tests, physician and nurse salaries, and drugs (informa-
tion on drug treatments was obtained from patient clinical 
records). Unit prices for medication were based on the ofﬁ  -
cial published 2007 prices.25 Unit prices of human resources 
costs (salaries) and BC interventions were provided by the 
hospital’s Planning and Finance Department. The average 
cost of medical equipment used (based on a 10-year depre-
ciation) was calculated similarly. Hospital overhead costs Risk Management and Healthcare Policy 2008:1 17
The costs of breast cancer in Mexican women
were calculated using administrative, cleaning, security, 
maintenance expenses, and the cost of consumables and 
general services associated with care given to women with 
BC. Transport costs for the patient and her accompanying 
person were measured (non direct medical costs).
Some assumptions were made: one US dollar was 
considered equivalent to 10.40 Mexican pesos (2007). 
Minimum and maxiumum average values were estimated 
for income loss due to illness, medical appointments, treat-
ment, and food. For women and accompanying persons 
who were housewives or not employed outside the home, 
the minimum wage for Mexico City in 2007 (US$147.82 
monthly) was assumed.
Current cost was calculated assuming a discount rate of 
5% per annum and 5 years of BC survival. No adjustment 
per year was done as any further chemotherapy treatment or 
surgery would be performed for women included in the pres-
ent investigation. Only the minimum and maximum present 
costs were considered.
Results
The clinical ﬁ  les of 506 women were examined, but only 
102 met the inclusion criteria. Only 102 patients were at 
stages I or II and were 35 years or older. Table 1 shows the 
characteristics of the 102 women included in the study: 43.1% 
(34) were aged 56 to 64; 34.4% (32) were aged 45 to 55; 92.2% 
(94) were at stages IIA or IIB and only 7.8% (8) were at stage I. 
82.4% (84) received modiﬁ  ed radical mastectomy (MRM) and 
17.6% (18) received conservative surgery (CS).
Medical records showed that 80.4% (82) of the women 
in the study were treated with ﬂ  uorouracil, epirubicin, cyclo-
phosphamide (FEC), 14.6% (15) with cyclophosphamide, 
methotrexate, ﬂ  uorouracil (CMF), and 4.9% (5) with other 
treatment combinations.
The results of the questionnaire applied to the 102 women 
included in the study are summarized in Table 1. The majority 
(57.9%) of women had only completed elementary education; 
23.5% (24) had completed ninth grade; and 14.7% (24) had 
completed technical or vocational training; 73.4% (75) of 
the women were not employed outside the home; 23.7% (24) 
were employed, and 2.9% (3) were self-employed.
Table 1 also shows data on accompanying persons and 
travel time to the hospital. Patients were accompanied by 
a son or daughter in 36.2% (37) of cases, and by a spouse 
in 30.4% (31) of the cases; 80.39% (82) of accompanying 
persons were not employed outside the home. Travel time 
to the hospital was 91 to 120 minutes for 39.21% (40) of the 
women, and less than 60 minutes for 36.27% (37).
Table 2 shows the information gained from the 
questionnaire on expenses (time and money). These data 
were used to calculate direct and indirect nonmedical costs 
related to expenses incurred by the patients.
Because 60.77% of subjects spent less than US$4.80 
per hospital visit, the average transport cost of US$4.80 
per visit was estimated (Table 2). Table 2 also shows that 
88.23% (90) of the women in the study said that they spent 
4 to 6 hours at the hospital; 73.4% (75) of the women were 
housewives, and applying the minimum wage yielded a cost 
of US$2.43. As shown in Table 2, seven patients (6.87%) 
spent less than US$4.80 on meals during hospital visits, for 
which an average value of US$4.32 is assumed; 11 patients 
(10.78%) spent between US$4.80 and US$9.60, and an aver-
age of US$5.28 is assumed for this group. For the calcula-
tion of loss of income (indirect costs) due to illness, only 
19 (18.63%) patients reported lost income (Table 2), at an 
average amount of US$144.24 per month for 6 months of 
treatment. The cost of dietary change was estimated to be 
US$115.38 per month (Table 2).
For medical expenses not covered by the social security 
system, the average was US$81.25 for the 19.6% (20) of 
patients who reported these expenses (Table 2). Other medi-
cal expenses due to the illness were reported by 56 patients 
(60.70%); the average cost for this group was US$96.49 per 
month (Table 2).
Table 3 shows the results of nonmedical direct and 
indirect costs grouped and calculated for the total sample 
(102 women), taking into consideration 6 visits per woman, 
6 months of treatment, and the number of patients who 
responded to each item in the questionnaire.
The total cost for transport was US$2,942.30 for the 
102 women included in the study (Table 3). The cost of meals 
for these 18 patients over 6 months of treatment was thus 
calculated as US$9553.84 (Table 3). Total cost of dietary 
change was US$70, 615.38 (Table 3). Total noncovered 
medical cost is reported as US$487.50 (Table 3). Other 
nonmedical expenses due to the illness were reported by 
56 patients (64.70%); the average cost for this group over 
6 months of treatment was US$5,235.57 (Table 3).
Total direct nonmedical costs were US$88,834.61. Total 
indirect costs of time at hospital were US$1312.61–US$1961.13 
and loss of income due to illness was US$16,442.30 (Table 3). 
Minimum and maximum total costs are shown in Table 3.
Table 4 shows that the costs for medical treatment and 
the cost per treatment cycle per patient was US$1140.38 
for FEC and US$1207.31 for CMF. The total cost for 
six treatment cycles was US$71,160.00 for FEC and Risk Management and Healthcare Policy 2008:1 18
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Table 1 Sociodemographic variables, type of surgery and chemotherapy data from questionnaire applied to 102 women with breast 
cancer
Value Number of patients %
Age 35–45 26 25.5
46–55 32 31.4
56–65 34 43.1
Stage I 8 7.8
IIA 47 46.1
IIB 47 46.1
Type of surgery Conservative 18 17.6
MRM 84 82.4
Chemotherapy CMF 15 14.6
FEC 82 80.4
Other 5 4.9
Level of education None 2 2
Elementary 59 57.9
9th grade 24 23.5
Technical/vocational 15 14.7
Post-secondary 2 2
Occupation Homewife 75 73.4
Employed 24 23.7
Self-employed 3 2.9
Accompanying person Spouse 31 30.40
Son or daughter 37 36.27
Brother or sister 14 13.72
Friend 15 14.70
Other 5 4.91
Occupation of accompanying person Housekeeper 82 80.39
Employed 18 17.64
Self-employed 2 1.97
Travel time to hospital 60 minutes 37 36.27
61–90 minutes 17 16.67
91–120 minutes 40 39.21
120 minutes 8 7.85
Abbreviations: CMF, cyclophosphamide, methotrexate, ﬂ  uorouracil; FEC, ﬂ  uorouracil, epirubicin, cyclophosphamide; MRM, modiﬁ  ed radical mastectomy.
US$7,783.85 for CMF. Data on treatments were obtained 
from the patient clinical records.
Table 4 shows the total sums of direct (medical and 
nonmedical) and indirect costs calculated for the average 
treatment period of 6 months for all patients. Only 97 of the 
102 women received FEC or CMF; the other ﬁ  ve women 
received other treatment combinations. Because of the high 
variability in cost of the other treatments, these ﬁ  ve patients 
are not included in the sum.
Total direct costs for women with MRM were US$733,821.15, 
and for women with CS were US$138,190.38 (Table 4). Total 
indirect costs ranged from a minimum of US$17,737.04 to 
a maximum of US$18,403.44 for an average 6 months of 
treatment for the two groups of women (102).
The total economic burden of illness for the study 
population (102), including direct and indirect costs, ranged 
from US$840.392.79 to US$841.059.21 for MRM and from 
US$244,762.04 to US$245,428.44 for CS (Table 4).
Time adjustment and discount rate
A general formula for discounting future cost was used.26 The 
minimum and maximum present values for MRM-treated 
women using a 5% discount rate, and ﬁ  ve years of survival 
were US$658,470.04 and US$658,992.19, respectively. Risk Management and Healthcare Policy 2008:1 19
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Table 2 Direct nonmedical and indirect costs classiﬁ  ed by type of cost and number and percent of patients from questionnaire applied 
to 102 patients with breast cancer
Item Value US dollars ($) # of patients Percentage (%)
Transportation $4.80 62 60.77
$4.90–$9.60 31 30.40
$9.70–$14.42 2 1.96
$14.51–$19.23 2 1.96
$19.23 5 4.91
Time at hospital 3 hours 4 3.93
4–6 hours 90 88.23
7 hours 8 7.84
Meals during hospital visit $4.80 7 6.87
$9.70–$14.42 11 10.78
None 84 82.35
Absence from work during treatment Yes 15 14.70
No 87 85.30
Loss of income $96.15 ($US/month) 4 3.93
$96.13–$192.30 ($US/month) 9 8.82
$192.30–$288.46 ($US/month) 3 2.94
$288.46 ($US/month) 3 2.94
None 83 81.37
Dietary changes $96.15 ($US/month) 75 73.52
$96.13–$192.30 ($US/month) 21 20.58
$192.30 ($US/month) 6 5.9
Noncovered medical expenses None 82 80.4
$48.07 ($US/month) 10 9.8
$48.7–$96.15 ($US/month) 4 3.92
$96.15–$192.30 ($US/month) 4 3.92
$192.30 ($US/month) 2 1.96
Other expenses related to the disease None 36 35.30
$48.07 ($US/month) 19 18.62
$48.07–$96.15 ($US/month) 19 18.62
$96.15–$192.30 ($US/month) 21 20.58
$192.30 ($US/month) 7 6.88
The minimum and maximum present values for CS-treated 
women using a 5% discount rate, and ﬁ  ve years of survival 
were US$191777.55 and US$192,299.69, respectively.
Discussion
Although the present study used a small sample and a 
relatively short period of time, the results are consistent 
with information suggesting that BC is detected at advanced 
stages in Mexico.7
Most woment in the present study received MRM. In the 
US, in contrast, researchers report that a greater proportion 
of women with BC receive CS than MRM.27 Patients who 
received CS tended to have a higher level of education than 
women who received MRM. The same relationship between 
level of education and treatment was found by Janz and 
colleagues.27 Women with more education might visit the 
doctor more often, or might be better informed about early 
detection of BC.
The majority of women in this study were not employed 
outside the home, unlike the US study by Janz and 
colleagues.27 In Mexico, unemployment is higher among 
women and in general, than in the US.
In the present study, 36.27% of the women were 
accompanied by a son or daughter, and 30.40% by a spouse. Risk Management and Healthcare Policy 2008:1 20
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The data on occupation of the accompanying person were 
similar to those in the study by Pandey and colleagues, which 
also found that the accompanying person tended to be an 
unemployed spouse or son or daughter.28 In the present study, 
80.39% of the accompanying persons were not employed 
outside the home.28
The majority of the women used buses, subway or both to 
get from their homes to the hospital. Due to the heavy trafﬁ  c 
in Mexico City, commuting “distances” are commonly mea-
sured in minutes and hours rather in kilometers, as they were 
in this study, making it impossible to draw comparisons with 
other studies. The time spent in hospital was 4 to 6 hours. 
These times are quite high, perhaps due to staff shortages in 
the social security system.29
Responses on expenses for meals and medications during 
hospital visits were quite varied. An average of US$5.29 was 
estimated which, if considered to include the accompanying 
person’s meal, is a reasonable amount for a lunch for two 
people given the cost of living in Mexico City.
The cost of dietary modiﬁ  cations was the highest com-
ponent of nonmedical expenses (US$70.615.38), which may 
mean that women diagnosed with BC make an extra effort 
to consume a balanced diet and less fat.
There should not have been any uncovered medical costs, 
as the social security system supposedly covers all medical 
expenses for beneﬁ  ciaries; nevertheless, 20 women indicated 
that they incurred such expenses. Most women (56) reported 
nonmedical expenses related to their illness. These could 
have been cosmetic items, for example wigs or prostheses.
FEC therapy was approximately 10% more expensive 
than CMF therapy, and MRM surgery cost approximately 
30% more than CS (US$2106.73 and US$1428.85 per patient 
respectively). The cost of medication was relatively low, as 
the social security system buys drugs by public tender and 
in bulk.
Total loss of income was estimated at US$16,442.31. 
However only a small number of women were employed 
outside the home, a minimum monthly wage of US$144.23 
was assumed, and costs were estimated based on only a 
six month period. It is likely that costs were underestimated 
due to the limitations of the present study. Total indirect 
Table 3 Direct nonmedical and indirect costs grouped and 
calculated for total sample (102 women) from responses to 
questionnaire and study assumptions
Item Cost (US$)
Transportation 2,942.30
Meals 9553.84
Dietary changes 70,615.38
Noncovered medical costs 487.50
Other nonmedical costs 5,235.57
Subtotal direct nonmedical costs 88,834.61
Indirect costs
Time at hospital (appointment or therapy) 1312.61–1961.13
Loss of income 16,442.30
Indirect costs subtotal 17,737.03–18,403.44
Minimum total costs 106,589.53
Maximum total costs 107,238.05
Table 4 Direct and indirect costs of chemotherapy with FEC or CMF per patient and for six months treatment (total patients, 97)
FEC ($US) 
per patient
CMF ($US) 
per patient
Cost MRM n = 82 ($US) Conservative S 
n = 15 ($US)
Drugs 1063.46 1220.38 Direct
Clinical and laboratory 
examinations
57.69 57.69 aChemotherapy 561,069.23 116,757.69
Consumables 9.61 9.61 Surgery 172,751.92 21,432.69
Equipment 
and infrastructure
3.84 3.84 Subtotal direct 733,821.15 138,190.38
Personnel 5.76 5.76 bSubtotal nonmedical 88,834.61
Subtotal per cycle 1140.38 1297.30 bSubtotal indirect 17,737.03–18,403.44
Total cost for 6 
chemotherapy 
cycles/patient
6842.30 7783.84 MRM total minimum 
and maximum
840,392.80 and 
841,059.21
CS total minimum 
and maximum
244,762.03–245,428.44
Notes: aCost per patient was multiplied by 6 (number of complete treatment cycles) and by the number of patients receiving FEC (80.4%) or CMF (14.7%) chemotherapy; 
bNonmedical and indirect costs were calculated from the questionnaire responses for all women with BC (102), not by type of surgery.
Abbreviations: CMF, cyclophosphamide, methotrexate, ﬂ  uorouracil; CS, conservative surgery; FEC, ﬂ  uorouracil, epirubicin, cyclophosphamide; MRM, modiﬁ  ed radical 
mastectomy.Risk Management and Healthcare Policy 2008:1 21
The costs of breast cancer in Mexican women
costs were US$17.737.03, including the cost of time spent 
at the hospital. In another Mexican study of a different 
chronic disease, indirect costs were much higher than IMSS 
direct costs.14
We can conclude from the results of this study that current 
social security practice should be modiﬁ  ed to enable early BC 
detection and decrease the direct and indirect costs associated 
with the disease. The present study makes a contribution to 
information that can be used to improve public health policy 
and improve programs for breast self-examination, both of 
which can aid early detection of BC.
Limitations
The number of patients was relatively small. The micro-
costing process has inherent limitations, as items could 
be either omitted or overestimated. The questionnaire had 
methodological limitations and limitations of scope. The 
results apply only to the sample and cannot be generalized 
to the entire Mexican or social security population. Further 
studies of the BC burden with greater numbers of patients 
are required.
Conclusions
The total economic disease burden in the study population 
was greater for women who received MRM than those who 
received CS. The direct costs of MRM are higher. Women 
with BC at stage I had higher levels of education. The major-
ity of women in the present study were of reproductive age. 
In spite of the small size of the sample population, the ﬁ  nding 
that BC is detected at advanced stages III and IV in Mexico 
was corroborated.
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